More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Zach Pitluk, Ph.D.
Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”